Answers are grounded in this paper and cite their sources.
Radium-223 dichloride ( 223 Ra) is an α-emitter approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with bone metastases, but without visceral involvement. Despite being a life-prolonging therapy (LPT), 223 Ra remains underutilized. A large body of real-world evidence (RWE) for 223 Ra has been published in the decade since the pivotal phase 3 ALSYMPCA study, a period during which the treatment landscape has continued to evolve. How to optimize 223 Ra use, including how to integrate it into the mCRPC management pathway amongst other current LPTs (i.e., with respect to timing and concurrent, layered, or sequential use), is therefore of considerable interest. RWE studies lack the conventional restraints of clinical trials and can therefore help to build an understanding of how treatments may be best used in routine practice. Here we review RWE studies investigating the efficacy and safety of 223 Ra in mCRPC [including in sequence with the recently approved 177-Lutetium conjugated to the ligand prostate-specific membrane antigen ( 177 Lu-PSMA)], as well as response marker development, imaging techniques, and current clinical practice recommendations.
No takes yet. Share an insight, caveat, or question.
O’Sullivan et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: